Rakhi Kumar

Healthcare Executive at Neuropace

Speaker

Rakhi Kumar has served on the board of directors and as chair of the Audit Committee of Neuropace (Nasdaq: NPCE) since April 2021. She most recently served as Chief Accounting Officer at Roivant Sciences (Nasdaq: ROIV) from 2015 to 2025, where she was integral to the founding team and held numerous leadership roles, including Vice President of Finance and a board member for Roivant Social Ventures and Treasurer. Ms. Kumar led and launched financial operations at Roivant’s biopharmaceutical subsidiaries and healthcare technology companies, overseeing Treasury, accounting, SOX and financial operations. In her capacity, she also played a pivotal role in guiding the company through multiple successful IPOs and was heavily involved in significant transactions, such as the go-public activities at Immunovant and Roivant via a SPAC, Roivant's $3B strategic alliance with Sumitomo Dainippon Pharma, Roivant’s $7.1B sale of Telavant to Roche and Roivant’s $1.2B sale of Dermavant to Organon.

Before joining Roivant, Ms. Kumar held various finance roles from 2013 to 2015 at The Medicines Company (acquired by Novartis) and from 2010 to 2013 at Barrick Gold. Earlier in her career, she worked in assurance services and at the national office at Ernst & Young from 2003 to 2010. Ms. Kumar is a member of the Financial Accounting Standards Board’s (FASB) Small Business Advisory Committee (SBAC). She is a licensed Certified Public Accountant in the United States, a Chartered Professional Accountant in Ontario, Canada, and she holds an M.S. in Accounting and Taxation from the University of Hartford.